Teprotumumab
E854987
Teprotumumab is a monoclonal antibody drug used primarily to treat thyroid eye disease by targeting the insulin-like growth factor-1 receptor (IGF-1R).
All labels observed (1)
| Label | Occurrences |
|---|---|
| Teprotumumab canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T10292249 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Teprotumumab Context triple: [Genmab, product, Teprotumumab]
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Teprotumumab Target entity description: Teprotumumab is a monoclonal antibody drug used primarily to treat thyroid eye disease by targeting the insulin-like growth factor-1 receptor (IGF-1R).
-
A.
Onpattro
Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
-
B.
Vitrakvi
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
-
C.
Zaltrap
Zaltrap is a cancer medication (brand name for aflibercept) used primarily in combination chemotherapy to treat metastatic colorectal cancer by inhibiting vascular endothelial growth factor (VEGF).
-
D.
aflibercept
Aflibercept is an anti-VEGF biologic drug used primarily to treat neovascular (wet) age-related macular degeneration and other retinal vascular diseases.
-
E.
Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
IGF-1R inhibitor
ⓘ
monoclonal antibody ⓘ |
| hasAbbreviation |
IGF-1R
ⓘ
linked to:
insulin-like growth factor-1 receptor
|
| hasAdministrationSetting | infusion center ⓘ |
| hasAntibodyType | IgG1 ⓘ |
| hasApprovalRegion |
United States
ⓘ
linked to:
United States of America
|
| hasApprovalYear | 2020 ⓘ |
| hasATCCode | L01FX15 ⓘ |
| hasBlackBoxWarning | false ⓘ |
| hasClinicalTrialPhaseAtApproval | Phase 3 ⓘ |
| hasCommonAdverseEffect |
alopecia
ⓘ
diarrhea ⓘ fatigue ⓘ hearing impairment ⓘ hyperglycemia ⓘ muscle spasm ⓘ nausea ⓘ |
| hasContraindication | pregnancy ⓘ |
| hasDeveloper | Horizon Therapeutics ⓘ |
| hasDosingRegimen | intravenous infusion every 3 weeks for 8 doses ⓘ |
| hasEffect |
improves clinical activity score in thyroid eye disease
ⓘ
improves diplopia ⓘ reduces proptosis ⓘ |
| hasIndication |
Graves orbitopathy
ⓘ
active thyroid eye disease ⓘ thyroid eye disease ⓘ thyroid-associated ophthalmopathy ⓘ
linked to:
Graves disease
|
| hasInitialDose | 10 mg/kg ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMechanismOfAction |
blocks IGF-1R signaling
ⓘ
inhibits IGF-1R autoantibody activation ⓘ reduces orbital fibroblast activation ⓘ reduces orbital inflammation ⓘ reduces tissue expansion behind the eye ⓘ |
| hasMolecularType | human monoclonal antibody ⓘ |
| hasRegulatoryApproval |
FDA
ⓘ
linked to:
Food and Drug Administration
|
| hasRouteOfAdministration | intravenous infusion ⓘ |
| hasSubsequentDose | 20 mg/kg ⓘ |
| hasTarget | insulin-like growth factor-1 receptor ⓘ |
| hasTargetSpecies | human ⓘ |
| hasTherapeuticArea |
endocrinology
ⓘ
ophthalmology ⓘ |
| hasTradeName | Tepezza ⓘ |
| hasWarning |
may cause infusion reactions
ⓘ
may worsen glycemic control in diabetic patients ⓘ |
| isAdministeredBy | healthcare professional ⓘ |
| isFirstInClass | true ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Teprotumumab Description of subject: Teprotumumab is a monoclonal antibody drug used primarily to treat thyroid eye disease by targeting the insulin-like growth factor-1 receptor (IGF-1R).
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.